Watanabe Todd sold $139K of ARQT
Watanabe Todd (See Remarks) sold 4,377 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $31.86 ($0.14M total) on 2026-11-02.
How this was made
The 30-second read
Why it matters
A modest insider sell that may cause short‑term pressure but is unlikely to affect long‑term valuation.
Market read
Primary disclosure of a small insider sale; limited trading relevance.
What to watch
Potential tax planning or liquidity needs of the insider, not necessarily a bearish signal.
Background
Form 4 filing discloses insider transactions required by SEC regulations.
Ticker impact
Officer/director Watanabe Todd sold 4,377 shares at $31.86 each, total $139,466, reducing his stake to 712,826 shares.
likely pressure as the market prices in the insider sell
Form 4 is a primary source; the transaction amount is small relative to market cap, so impact is limited.
Market effects
Minimal effect on the broader biotech sector; insider activity is routine.
US equity market, limited to ARQT shareholders.
Low
Counterpoint
The sale may be unrelated to company fundamentals and could be a routine portfolio rebalancing.
Key entities
- CompanyArcutis Biotherapeutics, Inc.
Biopharma developing dermatology treatments, ticker ARQT.
- IndividualWatanabe Todd
Officer and director of Arcutis Biotherapeutics.

